RT Journal Article
SR Electronic
T1 Reversal of Epigenetic Age with Diet and Lifestyle in a Pilot Randomized Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.07.20148098
DO 10.1101/2020.07.07.20148098
A1 Kara N. Fitzgerald
A1 Romilly Hodges
A1 Douglas Hanes
A1 Emily Stack
A1 David Cheishvili
A1 Moshe Szyf
A1 Janine Henkel
A1 Melissa W. Twedt
A1 Despina Giannopoulou
A1 Josette Herdell
A1 Sally Logan
A1 Ryan Bradley
YR 2020
UL http://medrxiv.org/content/early/2020/07/14/2020.07.07.20148098.abstract
AB Manipulations to set back biological age and extend lifespan in animal models are well established, and translation to humans has begun. The length of human life makes it impractical to evaluate results by plotting mortality curves, so surrogate markers of age have been suggested and, at present, the best established surrogates are DNA methylation clocks. Herein we report on a randomized, controlled clinical trial designed to be a first step in evaluating the effect of a diet and lifestyle intervention on biological age. Compared to participants in the control group (n=20), participants in the treatment group tested an average 3.23 years younger at the end of the eight-week program according to the Horvath DNAmAge clock (p=0.018). Those in the treatment group (n=18) tested an average 1.96 years younger at the end of the program compared to the same individuals at the beginning with a strong trend towards significance (p=0.066 for within group change). This is the first such trial to demonstrate a potential reversal of biological age. In this study, the intervention was confined to diet and lifestyle changes previously identified as safe to use. The prescribed program included multiple components with documented mechanistic activity on epigenetic pathways, including moderate exercise, breathing exercises for stress, and a diet rich in methyl donor nutrients and polyphenols.Competing Interest StatementKF and RH declare that they use the intervention described here in clinical practice, are named in a related patent application, and receive earnings from educational products associated with its use. Notably, KF and RH were not involved in the day-to-day conduct of the trial, collection of samples, or data analysis.Clinical TrialNCT03472820Funding StatementThis study was generously supported through an unrestricted grant from Metagenics, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the National University of Natural MedicineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings will be available in Gene Expression Omnibus at https://www.ncbi.nlm.nih.gov/geo/, submission number GSE 149747, from 04-14-23 following an embargo from the date of publication to allow for commercialization of research findings. https://www.ncbi.nlm.nih.gov/geo/